MINDSET 2
A clinical study testing medication for people with Alzheimer's disease.
What is the study about?
This study is looking at whether a new treatment can help improve memory, thinking and daily functioning in people with Alzheimer’s Disease. Current treatments only offer limited, short-term benefits, so new options are needed. The study is testing two related drugs (KarXT and KarX-EC), which researchers hope may improve symptoms. Early studies suggest one of the components may help with memory and thinking, while the other may reduce side effects.
What is involved?
Participants will be asked to go through a screening process to determine if you are eligible to take part. A member of the research team will go through your medical history and carry out some tests (screening tests). This may take up to six weeks. Eligible participants will move on to the Randomised Controlled Trial. They will be randomly allocated to take the trial medication or a placebo (dummy drug). This phase will last 24 weeks. After 24 weeks, the optional Open Label phase will begin and continue for another 24 weeks. During this phase, participants will all be invited to take the trial medication. Participants monitored closely during both parts of the trial with weekly appointments for the first four weeks of both phases, less frequently once it’s established that the participant is tolerated the medication and dose. Memory and functioning will be assessed at several points through out the study.
Who can take part?
Participants will be:
- Aged 65-80 years old
- Have a diagnosis of Alzheimer’s Disease
- Further criteria will be assessed at screening.
- Participants must have a study partner (caregiver) that is able to come to visits and help with study activities, including answering questionnaires.
How can people get involved?
Contact Lisa Hackney via email lisa.hackney1@nhs.net and look out for study posters on Trust sites.